Why? No reasons at all. Got to remember overall market down almost 10%. Looking at short term worthless. What will be interesting is if we get a special this quarter
Liza - ETP is certainly not dead money. Even if ETP had not grown at all it still paid out over 8% based on the price from then. EPTP is not the "best of breed" but is certainly a place to put some dollars. Today - not for me, but last novemeber when it kept bouncing off $41 it was a relative bargain. The big boys like EPD and MWE are flat since then. Picking the "best" MLP is a fools game as you well know. You can find a time frame where almost any MLP outpreformed the others. LT is what counts and ETP will provide security and a return for the future.
As to the financing costs being low - DUH! NS made some really bad decisions and have big credit and cash flow issues. ETP has a completely different business model with lots of cash flow and different sorts of assets and thus is investment grade.
After hours volumes are meaningless and signifiy nothing. Actually daily moves are pretty worthless too unless you have significant news or a longer term trend. NAVB has none of these now. It is going to sit until they get news of new approvals and/or data of income from Lymphoseek. Shorts are still betting on needing money before cash comes in.
EPD has not gapped up. You also ignore that EPD unlike many other MLPs has been able to finance over $1B of its capital needs internally for years. Retained earnings here are huge and growing. Last, while financing costs will certainly effect EPD they will effect it less as much long term financing is already in place and they will reap the benefits of the higher returns on some of their regulated assets with higher interest rates
What jump? EPD is still close to where it has traded for a couple months. Daliy moves not meaningful unless you are a fortune teller.
Clueless. All you have shown in MWE is growing its asset base faster than EPD. You are mixing capex with maintance capex.
MWE is not growing to move the unit price over the short term. They are investing for 2014 and way beyond. If you are a trader then sell. If a long term investor then hold for the future and higher CAGR on distributions that is coming.
AMPE is priced correctly at about $8. Until the results for their drugs are final the big $$ do not roll in. Agree significant short pressure as the news continues to be good but we are not home yet. Got to remember that ofeten days and weeks go by w/o news on AMPE. Patience.